Oleoylethanolamide
|
Basic information |
| Metabolite name | Oleoylethanolamide |
 | HMDB0002088 |
 |
C20792 |
 |
5283454 |
| Synonyms | Oleoylethanolamine; |
| No. of studies | 14 |
|
Basic information |
| Metabolite name | Oleoylethanolamide |
| HMDB0002088 |
|
C20792 |
|
5283454 |
| Synonyms | Oleoylethanolamine; |
| No. of studies | 14 |
|
Relationship between Oleoylethanolamide and depression (count: 14) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1007 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M498 | Type3 | acute escitalopram group vs. control group | Cerebellum | Wistar rat | Down |
| Study M498 | Type3 | acute N-acetylcysteine group vs. control group | Nucleus accumbens | Wistar rat | Down |
| Study M498 | Type3 | chronic N-acetylcysteine group vs. control group | Dorsal striatum | Wistar rat | Up |
| Study M498 | Type3 | chronic N-acetylcysteine group vs. control group | Hippocampus | Wistar rat | Up |
| Study M498 | Type3 | chronic escitalopram group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M498 | Type3 | acute imipramine group vs. control group | Hippocampus | Wistar rat | Up |
| Study M498 | Type3 | acute escitalopram group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M498 | Type3 | chronic N-acetylcysteine group vs. control group | Nucleus accumbens | Wistar rat | Down |
| Study M498 | Type3 | chronic N-acetylcysteine group vs. control group | Frontal cortex | Wistar rat | Up |
| Study M498 | Type3 | acute imipramine group vs. control group | Cerebellum | Wistar rat | Down |
| Study M498 | Type3 | chronic imipramine group vs. control group | Dorsal striatum | Wistar rat | Up |
| Study M498 | Type3 | acute URB597 group vs. control group | Hippocampus | Wistar rat | Down |
| Study M498 | Type3 | chronic escitalopram group vs. control group | Cerebellum | Wistar rat | Down |
| Study M498 | Type3 | chronic URB597 group vs. control group | Hippocampus | Wistar rat | Down |
| Study M498 | Type3 | chronic tianeptine group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M503 | Type2 | SDS + URB694 group vs. SDS group | Plasma | Wistar Kyoto rat | Up |
| Study M504 | Type2 | Dysbiotic + probiotic group vs. Dysbiotic group | Duodenum | C57/BL6 mouse | Down |
| Study M557 | Type2 | MDD group, after vs. before prescribed moderate exercise | Serum | Human | Up |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, validation cohort | Plasma | Human | Down |
| Study M712 | Type1 | depression group vs. control group | Hippocampus | Cynomolgus monkey | Up |
| Study M784 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M784 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M784 | Type2 | CUMS + liquiritin group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M811 | Type2 | CUMS + middle dose of dipyrone group vs. CUMS group | Amygdala | Balb/c mouse | Up |
| Study M823 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M993 | Type1 | depression group vs. control group | Plasma | Human | Up |